Table 2.
References | Sample type | Clinical parameters | miRs deregulated | miRs selected as candidate biomarkers | |
---|---|---|---|---|---|
Taylor et al. (2010) [24] | 113 PCa tissues 28 normal tissues |
Large screening study | Taylor et al. 10.1016/j.ccr.2010.05.026 | ||
| |||||
Martens-Uzunova et al. (2012) [44] | 102 PCa tissues and normal adjacent tissues | High risk biochemical recurrence | 12 upregulated 13 downregulated |
miR-19a, miR-130a, miR-20a/106/93 |
↑ |
miR-27, miR-143, miR-221/222 |
↓ | ||||
| |||||
Tong et al. (2009) [53] |
40 FFPE prostatectomy Specimens (20 without early BCR 20 with early BCR) |
Biochemical recurrence | 2 upregulated 4 downregulated |
miR-135, miR-194 (40% of case) |
↑ |
miR-145, miR-221, miR-222 |
↓ | ||||
| |||||
Schaefer et al. (2010) [54] | 76 PCa and adjacent normal tissues | Biochemical recurrence | 5 upregulated 10 downregulated |
miR-96 | ↑ |
| |||||
Hulf et al. (2013) [55] | 149 PCa and 30 matched normal tissues | Biochemical recurrence | 1 downregulated | miR-205 | ↓ |
| |||||
Schubert et al. (2013) [62] | BCR tissues and disease-free tissues | Biochemical recurrence | 2 downregulated | let-7b and let-7c | ↓ |
| |||||
Leite et al. (2011) [66] | 21 frozen BCR tissues 28 frozen disease-free tissues |
Biochemical recurrence | 4 upregulated | miR-100 | ↑ |
| |||||
Karatas et al. (2014) [72] | 82 PCa tissues (41 BCR and 41 disease-free) |
Biochemical recurrence | 3 downregulated | miR-1, miR-133b | ↓ |
| |||||
Selth et al. (2013) [102] | Serum samples from PCa patients (BCR = 8) disease-free = 8) |
Biochemical recurrence | 3 upregulated | miR-194 miR-146-3p | ↑ |
| |||||
Shen et al. (2012) [87] | Plasma samples from PCa (n = 82) | Castration resistance | 2 upregulated | miR-21, miR-145 | ↑ |
| |||||
Jalava et al. (2012) [90] | 28 primary PCa tissues 14 CRPC tissues 12 BPH tissues |
Castration resistance | 4 upregulated 3 downregulated |
miR-32, miR-148a, miR-590-5p, miR-21 |
↑ |
miR-99a, miR-99b, miR-221 |
↓ | ||||
| |||||
Peng et al. (2011) [94] | 6 primary PCa tissues 7 bone metastatic tissues |
Metastasis | 5 downregulated | miR-508-5p, miR-143, miR-145, miR-33a, miR-100 |
↓ |
| |||||
Saini et al. (2011) [95] | 36 PCa tissues 8 metastatic tissues 8 normal tissues |
Metastasis | 1 downregulated | miR-203 | ↓ |
| |||||
Mitchell et al. (2008) [19] | Serum samples from metastatic PCa (n = 25) and age-matched HD (n = 25) | Metastasis | 6 deregulated | miR-141 | ↑ |
| |||||
Brase et al. (2011) [100] | Serum samples from localized PCa (n = 14) and metastatic PCa (n = 7) | Metastasis | 5 upregulated | miR-141, miR-375 | ↑ |
| |||||
Bryant et al. (2012) [48] | Serum samples from PCa (n = 72) and metastatic PCa (n = 47) Plasma samples from PCa (n = 55) and metastatic PCa (n = 24) |
Metastasis | 2 upregulated | miR-141 and miR-375 | ↑ |
| |||||
Nguyen et al. (2013) [103] | Serum samples from localized PCa (n = 58) and metastatic CRPC (n = 26) | Castration resistance | 3 upregulated 1 downregulated |
miR-141, miR-375, miR-378∗ |
↑ |
miR-409-3p | ↓ | ||||
| |||||
Zhang et al. (2011) [88] | Serum samples from localized PCa (n = 20), ADPC (n = 20), CRPC DTX treated (n = 10) and BPH (n = 6) | Castration resistance | 1 upregulated | miR-21 | ↑ |
FFPE: formalin-fixed, paraffin-embedded, BCR: biochemical recurrence, Pca: prostate cancer, CRPC: castration resistant prostate cancer, BPH: benign prostatic hyperplasia, HD: healthy donors.